Sarah Higgins - Paratek Pharmaceuticals Executive
| PRTKDelisted Stock | USD 2.18 0.00 0.00% |
Executive
Ms. Sarah Higgins is appointed as Interim Principal Financial Officer and Principal Accounting Officer of the Company, effective April 5, 2019. Ms. Higgins joined the Company in March 2015 as Controller and was promoted to Vice President in July 2017. Prior to joining the Company, she spent nine years at Millennium Pharmaceuticals, Inc., now the oncology business of Takeda Pharmaceutical Company Limited, in financial roles of increasing responsibility and scope from March 2006 to December 2014 since 2019.
| Age | 48 |
| Tenure | 5 years |
| Phone | 617 807 6600 |
| Web | https://paratekpharma.com |
Paratek Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1799) % which means that it has lost $0.1799 on every $100 spent on assets. This is way below average. Paratek Pharmaceuticals' management efficiency ratios could be used to measure how well Paratek Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Paratek Pharmaceuticals currently holds 258.41 M in liabilities with Debt to Equity (D/E) ratio of 3.2, implying the company greatly relies on financing operations through barrowing. Paratek Pharmaceuticals has a current ratio of 3.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Paratek Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matthew Ritter | Equillium | N/A | |
| Wendy MD | Jasper Therapeutics | N/A | |
| Edwin MD | Jasper Therapeutics | 52 | |
| John Lunger | Adaptimmune Therapeutics Plc | 54 | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| Cintia PharmD | Adaptimmune Therapeutics Plc | 50 | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| David MD | Jasper Therapeutics | N/A | |
| John Bishop | Lyra Therapeutics | 62 | |
| Ronan JD | Lyra Therapeutics | 51 | |
| Robert Richard | Lyra Therapeutics | 66 | |
| MD BA | Adaptimmune Therapeutics Plc | 60 | |
| Dennis Williams | Adaptimmune Therapeutics Plc | N/A | |
| Philippe Ledru | Aptose Biosciences | 56 | |
| Indira Naidu | Immutep Ltd ADR | N/A | |
| MD MSc | Immutep Ltd ADR | N/A | |
| Allison Nance | Lyra Therapeutics | N/A | |
| Mary Sandin | Affimed NV | N/A | |
| Roger BSc | Aptose Biosciences | N/A | |
| Michael Moore | Equillium | N/A | |
| BA ACA | Adaptimmune Therapeutics Plc | 54 | |
Management Performance
| Return On Asset | -0.18 |
Paratek Pharmaceuticals Leadership Team
Elected by the shareholders, the Paratek Pharmaceuticals' board of directors comprises two types of representatives: Paratek Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Paratek. The board's role is to monitor Paratek Pharmaceuticals' management team and ensure that shareholders' interests are well served. Paratek Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Paratek Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Ex Chairman | ||
| FACC FAHA, CEO Director | ||
| Karen McGrath, VP HR | ||
| Sarah Higgins, Interim Principal Financial Officer and Principal Accounting Officer | ||
| Ben Strain, VP CEO | ||
| William Haskel, Senior Vice President General Counsel, Corporate Secretary | ||
| Adam Woodrow, Vice President and Chief Commercial Officer | ||
| Jason Burdette, VP Operations | ||
| Randall Brenner, Chief Officer |
Paratek Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Paratek Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.18 | |||
| Profit Margin | (0.35) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 345.3 M | |||
| Shares Outstanding | 57.32 M | |||
| Shares Owned By Insiders | 11.70 % | |||
| Shares Owned By Institutions | 55.08 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Earning | (5.49) X | |||
| Price To Sales | 0.86 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |